Insight, China's Pharmaceutical Industry

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...

Company Deals

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

Fineline Cube Jun 9, 2026

Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China-based Clinical Research Organization (CRO), announced...

Company Drug

Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations

Fineline Cube Jun 9, 2026

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...

Company Drug

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

Fineline Cube Jun 9, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today...

Company Deals Drug

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

Fineline Cube Jun 9, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...

Company Deals

Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology

Fineline Cube Jun 9, 2026

Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive...

Others

GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio

Fineline Cube Jun 9, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026

PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61...

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Fineline Cube Jun 8, 2026

Sino Medical Sciences Technology Inc. (SHA: 688108) announced it has received marketing approval from Colombia’s...

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026

Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at...

Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented positive Phase 2 results for zenagamtide (amycretin), its investigational...

Company Drug

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Fineline Cube Jun 8, 2026

Oricell Therapeutics Co., Ltd. announced it has received clearance from China’s National Medical Products Administration...

Company Drug

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Fineline Cube Jun 8, 2026

Boehringer Ingelheim announced positive results from two global Phase III trials of survodutide (BI 456906),...

Others

Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials

Fineline Cube Jun 8, 2026

Eli Lilly and Company (NYSE: LLY) announced additional positive results from pivotal Phase III trials...

Company Drug

Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

Fineline Cube Jun 8, 2026

Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical...

Company Drug

Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 – Novel αCD3×TGF-β Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models

Fineline Cube Jun 8, 2026

Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel αCD3×TGF-β bispecific fusion...

Company Drug

Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 – First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy

Fineline Cube Jun 8, 2026

Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against...

Company Drug

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Jun 8, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced the official commercial launch of Winrevair (sotatercept)...

Insight, China's Pharmaceutical Industry

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases

Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform

Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors

Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology

GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials

Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 – Novel αCD3×TGF-β Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models

Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 – First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

You Missed

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia